Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01819922 · ClinicalTrials.gov registry record · Phase 1

Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters

A Phase 1 study of Healthy, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT01819922 is a Phase 1 study of Healthy that has completed, run by Pfizer. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01819922, a Phase 1 study of Healthy, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG PF-05175157

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2013-04
Est. Completion 2013-10
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01819922

The ClinicalTrials.gov registry entry for NCT01819922 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01819922 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01819922 about?

NCT01819922 is a clinical study titled "Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters". This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.

What is the current status of trial NCT01819922?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2013-04. Estimated completion is 2013-10.

What conditions does trial NCT01819922 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01819922?

The interventions under investigation include: Placebo (DRUG), PF-05175157 (DRUG).

Who is sponsoring clinical trial NCT01819922?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01819922 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.